Ratings Xenetic Biosciences, Inc.

Equities

XBIO

US9840156023

Delayed Nasdaq Other stock markets 08:24:28 16/05/2024 pm IST			5-day change	1st Jan Change
3.77 ^USD	-4.69%		-6.72%	+9.27%

09/05	Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
21/03	Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
XENETIC BIOSCIENCES, INC.	+9.27%	6.09M	-
VERTEX PHARMACEUTICALS INCORPORATED	+7.45%	113B	B+
REGENERON PHARMACEUTICALS, INC.	+11.15%	106B	B+
ARGENX SE	+0.38%	22.27B	B
BIONTECH SE	-11.98%	22.22B	B+
GENMAB A/S	-5.99%	19.43B	A-
WUXI APPTEC CO., LTD.	-37.85%	17.87B	A-
BEIGENE, LTD.	-6.21%	17.24B	B
NEUROCRINE BIOSCIENCES, INC.	+6.92%	14.29B	C+
SAREPTA THERAPEUTICS, INC.	+34.95%	12.52B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes